Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF
February 12 2018 - 9:11PM
Business Wire
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it will
hold a webcast and conference call tomorrow, February 13, 2018, at
8:30 a.m. ET. The purpose of this conference call is to discuss
topline results from an ongoing Phase 2 clinical trial evaluating
KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor,
in patients with idiopathic pulmonary fibrosis (IPF) who were
previously treated with or offered pirfenidone and/or
nintedanib.
Webcast and Conference Call Information
To access the webcast, please visit the Investors section of
www.kadmon.com, under “Presentations & Events,” or by visiting
https://edge.media-server.com/m6/p/ntwshyjk. The call can be
accessed by dialing (866) 762-3021 with the Conference ID #3694419.
A replay of the webcast will be archived on the Company's website
for 30 days.
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical
company developing innovative products for significant unmet
medical needs. We have a product pipeline focused on fibrotic and
inflammatory diseases.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements may be preceded by the words “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “targets,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” or the negative of these terms or other
similar expressions. Forward-looking statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. We believe that these factors include, but are not
limited to, (i) the initiation, timing, progress and results of our
preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product
candidates into, and successfully complete, clinical trials; (iii)
our reliance on the success of our product candidates; (iv) the
timing or likelihood of regulatory filings and approvals; (v) our
ability to expand our sales and marketing capabilities; (vi) the
commercialization of our product candidates, if approved; (vii) the
pricing and reimbursement of our product candidates, if approved;
(viii) the implementation of our business model, strategic plans
for our business, product candidates and technology; (ix) the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
technology; (x) our ability to operate our business without
infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other
claims; (xii) regulatory developments in the United States, Europe
and other jurisdictions; (xiii) estimates of our expenses, future
revenues, capital requirements and our needs for additional
financing; (xiv) the potential benefits of strategic collaboration
agreements and our ability to enter into strategic arrangements;
(xv) our ability to maintain and establish collaborations or obtain
additional grant funding; (xvi) the rate and degree of market
acceptance, if any, of our product candidates; (xvii) developments
relating to our competitors and our industry, including competing
therapies; (xviii) our ability to effectively manage our
anticipated growth; (xix) our ability to attract and retain
qualified employees and key personnel; and/or (xx) our ability to
achieve cost savings and benefits from our efforts to streamline
our operations and to not harm our business with such efforts. More
detailed information about Kadmon and the risk factors that may
affect the realization of forward-looking statements is set forth
in the Company's filings with the U.S. Securities and Exchange
Commission (“SEC”), including the Company's Quarterly Report on
Form 10-Q filed pursuant to Section 13 of the Securities Exchange
Act of 1934, as amended, with the SEC on November 9, 2017.
Investors and security holders are urged to read these documents
free of charge on the SEC's web site at www.sec.gov. The Company
assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180212006440/en/
Kadmon Holdings, Inc.Ellen Tremaine, 646-490-2989Investor
Relationsellen.tremaine@kadmon.com
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Sep 2023 to Sep 2024